Experimental drug takes aim at deadly lung complication
NCT ID NCT07486869
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small study will test a drug called emapalumab in 5 adults with a rare, rapidly worsening lung disease linked to dermatomyositis. The drug is already used for a similar immune overreaction condition. Researchers will check if it improves oxygen needs, lung function, and CT scans over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Emapalumab
- What this could lead to
- If it works, this could point toward a treatment for a rare, life-threatening lung condition that currently has few options.
- What could go wrong
- This is a very small, early proof-of-concept study with only 5 people. It may not show clear benefit, and emapalumab can have serious side effects like infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-MDA5 ANTIBODY POSITIVE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami Hospital and Clinics
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can arm workouts boost oxygen use in lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- Can a targeted immune drug calm rare muscle inflammation?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD